binx health, a Boston, MA-based healthcare technology and diagnostics company, closed a Series E financing of $104m.
The round was led by OrbiMed, with participation from new investors Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian Global, and existing investors LSP and Johnson and Johnson Development Corporation, among others. In connection with the financing, Andrew Goldman, Co-founder and Managing Partner of Hildred Capital Management, will join binx health’s Board of Directors.
The company intends to use the funds to expand its business reach, ramp manufacturing, scale its proprietary binx
io testing instrument and cartridges, expand its sales efforts in the U.S. and abroad, and further build out its proprietary software platform and data infrastructure.
binx health Raises $104 Million in Series E Financing
- Financing led by OrbiMed, and includes Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian Global -
- Proceeds to support expansion of manufacturing for first-of-kind, FDA-cleared, CLIA-waived binx io rapid molecular diagnostic test, menu expansion, and the company s data and software architecture for its at-home and in-clinic businesses -
News provided by
Share this article
Share this article
BOSTON, May 27, 2021 /PRNewswire/ binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study and shop, today announced the closing of a Series E financing of $104 million. The financing was led by OrbiMed, and included other new investors Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian Global, along with existing investors LSP and Johnson and Johnson Development Corporation, am
Investors Continue to Support Breakthrough Research on Infant Gut Health
Evolve s final round of funding will help further the brand s goal of resolving Newborn Gut Deficiency in the U.S.
News provided by
Share this article
DAVIS, Calif., May 25, 2021 /PRNewswire/
Evolve BioSystems, Inc., a privately-held leading microbiome company, announced today the second and final close of its Series D round of funding exceeding $65 million, led by investors Cargill and Manna Tree. Oversubscribed from original expectations, this second closing of the Series D will accelerate the company s mission to research and address Newborn Gut Deficiency (NGD), a dramatic shortage of key good bacteria in the infant gut microbiome, and thus improve the health of infants worldwide.
The new Messina Hof Harvest Green Winery & Kitchen in Richmond, Texas
The Bonarrigo family (left to right): Karen Bonarrigo, chief administrative officer and wife of Paul M. Bonarrigo, chief executive officer and head winemaker; their children, Sophia and Paul Anthony; and Merrill and Paul V. Bonarrigo, co-founders of Messina Hof Wine Cellars.
When Paul V. and Merrill Bonarrigo first opened Messina Hof Wine Cellars in Bryan, Texas in 1977, they had one acre of vineyard planted with 50 different varieties of grapes. Over the years, the winery grew, and couple added two more locations. Messina Hof Hill Country Winery and Manor Haus in Fredericksburg, TX opened in 2011 and the Messina Hof Grapevine Winery in Grapevine, TX followed in 2014. This month, their son, Paul M. Bonarrigo and his wife Karen, launched the Messina Hof Harvest Green Winery & Kitchen in Richmond, TX, just outside of Houston.
Arcellx Appoints Rami Elghandour as Chairman and Chief Executive Officer
January 26, 2021 16:00 ET | Source: Arcellx, Inc. Arcellx, Inc. Gaithersburg, Maryland, UNITED STATES
GAITHERSBURG, Md., Jan. 26, 2021 (GLOBE NEWSWIRE) Arcellx, a privately held clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies, today announced the appointment of Rami Elghandour as Chairman of the Board and Chief Executive Officer, effective Jan. 22, 2021. Arcellx’s founder and CEO, David Hilbert, Ph.D., will transition to the new role of Chief Technical Officer.
“I’m thrilled to join Arcellx and honored to lead the company as it advances its transformative cancer and autoimmune therapies,” said Rami Elghandour. “The results from Arcellx’s Phase I study in multiple myeloma validate the company’s proprietary technology and demonstrate the potential for a best-in-class therapy for many patients in ne